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Ewing sarcoma (ES) is the second most common type of primary bone malignancy in children and young adults. Survival rates for
localized ES have improved to upwards of 70% with aggressive chemotherapy and local control. On the other hand, there has been
little improvement in survival rates for patients with metastatic or recurrent ES. Herein we review the diﬀerent current therapeutic
approaches available, including the diﬀerent upfront and salvage chemotherapy regimens, the role for stem cell transplantation,
and potential use of immunotherapy.
1.Background
Ewing sarcoma (ES) is the second most common type of
primary bone malignancy in children and young adults, and
age of onset is most often in the second decade, with a slight
male predominance [1]. The ES family of tumors is a group
of small round blue cell neoplasms of neuroectodermal
origin, which includes classical ES, primitive neuroectoder-
mal tumors (PNETs), and Askin tumors of the chest wall.
In the pre-chemotherapy era, less than 10% of patients
with ES survived. In the current era of multimodality
therapy, event free survival (EFS) rates have increased to
greater than 70% for localized disease [2, 3]. Conventional
treatment regimens for localized ES vary but in general
consist of a combination of the following chemotherapeu-
tic agents: vincristine, actinomycin-D, cyclophosphamide,
doxorubicin, ifosfamide, and etoposide. Adjunctive surgical
resection with or without radiation therapy is used for local
control.InNorthAmerica,the5-drugregimenofvincristine,
doxorubicin, and cyclophosphamide (VDC) alternating with
ifosfamide and etoposide (IE) is considered standard. The
Children’s Oncology Group (COG) has reported a 73% EFS
rate utilizing an interval compression strategy with this 5-
drug alternating regimen [3].
On the other hand, there has been little improve-
ment in survival rates for patients with metastatic or
recurrent ES despite aggressive treatment. Approximately
25% of patients present with metastatic disease at diag-
nosis, with the lung and bone being the most com-
mon sites of disease spread. For metastatic ES, the 5-
year EFS is approximately 30%, although isolated pul-
monary metastasis is associated with better prognosis
[4].
Most episodes of disease recurrence occur after com-
pletion of therapy and most recurrences (approximately
80%) occur within 2 years of initial diagnosis [5]. The
time to disease recurrence is the most important indicator
o fo v e r a l ls u r v i v a l( O S ) .L a t er e c u r r e n c e( >2y e a r sf r o m
diagnosis) carries an OS rate of greater than 25% while early
recurrence is associated with an OS rate of less than 10%
[6]. Although there has been limited success with current
conventional treatment options for both metastatic and
recurrent ES, newer therapeutic agents are on the horizon. In
this paper, we will review the current therapeutic approaches
for both metastatic and recurrent ES, including the diﬀerent
upfront and salvage chemotherapy regimens, the role for
stem cell transplantation (SCT), and potential future use of
immunotherapy.2 Sarcoma
2. MetastaticEwingSarcoma
2.1. Systemic Therapy. First-line therapy for metastatic ES
is similar to that for localized disease and utilizes the
same chemotherapy backbone with adequate local control
to both primary and metastatic sites. While this strategy
often results in complete or partial responses, OS rates
remain dismal at 20% [7]. Attempts to improve outcomes
through changes in chemotherapy regimens have been
largely unsuccessful. The INT-0091 study from the COG
reported no beneﬁt with the addition of IE to a stan-
dard backbone of vincristine, actinomycin-D, cyclophos-
phamide, and doxorubicin (VACD) [8]. In the second
Intergroup Ewing Sarcoma Study (IESS-2), the addition
of 5-ﬂuorouracil (5-FU) failed to improve outcome in
this subset of patients [9]. In a phase II trial from the
Pediatric Oncology Group, high-dose alkylator therapy with
topotecan or topotecan plus cyclophosphamide did not
improve patient outcomes; however, the latter combination
did show activity against metastatic disease (response rate
of 57%). The combination of topotecan and cyclophos-
phamide will be further evaluated in future COG trials
[10, 11].
2.2. Local Control. Currently, upfront whole-lung irradi-
ation is often used in patients with lung metastases,
regardless of radiographic response following neoadju-
vant chemotherapy. The strongest evidence for this comes
from the European Intergroup Cooperative Ewing Sarcoma
Study (EICESS) group, which reported an EFS rate of
38% (versus 27% in nonirradiated patients) using 15
to 18Gy whole lung irradiation in patients with iso-
lated lung metastases [12]. Unlike osteosarcoma, there
is little role for pulmonary metastasectomy in these
patients.
Data from the recently concluded EURO-E.W.I.N.G. 99
trial emphasizes the value for aggressive local control for
extrapulmonary metastatic ES. Signiﬁcant improvement in
EFS rates was observed with combined surgery and radiation
(56% EFS) compared to either modality alone (34% EFS)
[13]. Metastatic sites of disease in bone and soft tissues
shouldreceivefractionatedradiationtherapywithtotaldoses
of 45 to 56Gy, although care should be taken in limiting the
amount of bone marrow included in the radiation ﬁeld so as
toavoidcompromisingtotaldosesofsystemicchemotherapy
[14].
2.3. Role of Stem Cell Transplantation (SCT). The role
for high-dose myeloablative chemotherapy with autologous
stem cell rescue in patients with metastatic ES at initial
diagnosis remains controversial. The rationale for autol-
ogous SCT is that ES is highly sensitive to high-dose
alkylator therapy, but because of steep dose-response curves,
relatively small dose reductions can result in sharp decreases
in log tumor cell kill [15]. Some reports have shown
improved outcomes with this approach whereas others did
not. However, due to the paucity of prospective, randomized
trials, studies that do suggest a beneﬁt with this modality are
subject to selection bias as only a highly selective subgroup
of patients who achieve disease remission are eligible to
undergo SCT.
The largest reported experience that suggests a beneﬁt
with high dose therapy (HDT) with SCT is from the
European Bone Marrow Transplant Registry (EBMTR) data.
Although the EFS rate for extrapulmonary metastatic ES was
only 21%, improved outcome was observed in the subgroup
of patients treated with a busulfan-containing regimen.
In those patients that received busulfan in combination
with melphalan, 5-year OS rate was 44%, compared with
only 23% for patients who did not receive this drug
[16]. One prospective Children’s Cancer Group (CCG)
study investigated the eﬃcacy of melphalan, etoposide
and 12-Gy total body irradiation (TBI) with autologous
SCT in 32 patients with ES metastatic to the bone/bone
marrow. This regimen, however, did not improve survival
compared with conventional therapy (2-year EFS of 24%)
[17]. The EURO-EWING 99 trial is thus far the largest
and only randomized study to compare autologous SCT
with conventional therapy for patients with metastatic ES.
In their recently published data, they reported improved
outcome after HDT in those patients who achieved com-
plete remission prior to HDT (3-year EFS rate of 57%)
[18]. This reiterates previous reports of pre-SCT remission
status as an important prognostic factor in metastatic
ES.
2.4. Treatment Options under Clinical Evaluation. Alternate
approaches have looked into targeting tumor vasculature
using low-dose chemotherapy given over an extended period
of time (metronomic chemotherapy). The rationale for this
approach is that EWS-FLI1 in ES functions as a promoter
for vascular endothelial growth factor (VEGF) [14]. COG
has recently concluded a pilot study, AEWS02P1, which
adds the antiangiogenic agents vinblastine and celecoxib
to the standard backbone of vincristine, actinomycin-D,
cyclophosphamide, doxorubicin, ifosfamide, and etoposide
(VACD/IE). Results from this study are still pending.
The mammalian target of rapamycin (mTOR) pathway
is implicated in cell proliferation in certain malignancies
including ES. It is also postulated that mTOR may serve
as an important auxiliary pathway in tumor angiogenesis.
Rapamycin (also known as sirolimus), a highly speciﬁc
mTOR inhibitor, has demonstrated the ability to arrest ES
cell proliferation at the G1 phase and also downregulate
levels of EWS/FLI-1 proteins [19]. Also, low-dose rapamycin
has been shown to inhibit ES tumor growth by inhibit-
ing neovascularization, possibly via COX-2 suppression
[20].
Zoledronic acid is a bisphosphonate that has been shown
to be eﬀective as adjunctive treatment in primary and
metastatic bone tumors. Its mechanism of action in ES is
believed to be via induction of apoptosis and inhibition
of primary bone tumor growth through a mechanism that
involves the upregulation of osteoprotegerin. Preclinical data
in murine xenograft models demonstrated that primary
tumor growth is inhibited in 66% of cases with zoledronic
acid alone and in 88% of cases when combined with
paclitaxel [21].Sarcoma 3
3. RecurrentEwingSarcoma
3.1. Salvage Therapy. For patients with relapsed ES, the out-
look is dismal, with a 5-year OS rate of 10%. Patients whose
recurrence occurs after 2 years of diagnosis fare better, with
an OS rate closer to 25%. Most salvage regimens incorporate
previously used active agents along with newer second-line
camptothecin-derived agents. Topotecan and irinotecan are
topoisomerase I inhibitors that are derived from the nat-
urally occurring compound camptothecin. Camptothecin-
containing regimens have demonstrated eﬃcacy for patients
withrecurrentES.Whiletopotecanmonotherapyhaslimited
activity against ES, topotecan combined with cyclophos-
phamide produces response in 30%–35% of patients with
relapsed ES [22]. The combination of irinotecan and
temozolamide has also demonstrated activity in recurrent
ES. The group from Memorial Sloan-Kettering reported a
63% response rate in 19 patients treated with this regimen
[23]. Others have shown beneﬁt in the use of carboplatin-
based regimens for these patients. One such regimen is
ICE (ifosfamide, carboplatin, and etoposide) reinduction
which showed an overall response rate of 48% in a CCG
study of 21 patients with relapsed ES [24]. The combina-
tion of docetaxel and gemcitabine has also been reported
to achieve objective responses in cases of recurrent ES
[25].
3.2. Role of Stem Cell Transplantation (SCT). HDT followed
by autologous SCT may be beneﬁcial for a select subset
of patients with recurrent ES who respond favorably to
salvage therapy. Data to support this approach, however, is
lacking as most studies do not conﬁne their investigation
to recurrent ES in particular. A group from the University
of Washington investigated this approach speciﬁcally in
patients with recurrent EFS using busulfan, melphalan, and
thiotepaastheconditioningregimenandobservedimproved
survivalratesinthosepatientswithchemosensitiverecurrent
disease (5-year EFS and OS rates of 61% and 77%, resp.)
[26]. Allogeneic SCT is a potential alternative strategy for
recurrent ES but carries with it the risk for added morbidity.
The rationale behind the use of allogeneic SCT is based on
the potential immunogenicity of major histocompatibility
(MHC) molecules and tumor antigens expressed on ES
cells to elicit a graft-versus-tumor eﬀect [27]. There is also
preliminary clinical data to suggest that donor NK cells
may exert antitumor activity following allogeneic SCT and
promotes further investigation into the use of killer cell
immunoglobulin-like receptor- (KIR-) HLA-mismatched
SCT [28]. In one series from the EICESS group of 17 patients
with high-risk ES, four subjects received allogeneic SCT,
and three of these subjects experienced long-term disease-
free survival [29]. Conversely, Burdach et al. reported no
advantage in survival outcome with the use of allogeneic
SCT and also documented a much higher rate of transplant-
related mortality (40% compared to 19% following autol-
ogous SCT) [30]. Our institution previously published a
case of a 4-year-old female with recurrent metastatic ES
who achieved long-term remission following allogeneic SCT
[31].
3.3. Immunotherapy and Other Treatment Options under
Clinical Evaluation. COG is currently evaluating a number
of newer chemotherapeutic agents against ES in phase II
trials. Other agents under evaluation include vinorelbine, a
semisynthetic vinca alkaloid; trabectedin, which causes DNA
backbone cleavage and tumor cell apoptosis by superoxide
formation; oxaliplatin, a third generation platinum agent;
pemetrexed, a novel antifolate compound.
An increased understanding of the events involved in
ES tumorigenesis has allowed investigation into therapies
against key targets such as EWS/FLI1, IGF-1, CD99, and
angiogenesis pathways. The IGF system contributes to cellu-
larproliferationandimmortalityinawidevarietyofcancers,
includingES.InES,theEWS/FLI1fusionproteinrequiresthe
IGF1 receptor for malignant transformation of ﬁbroblasts in
vitro [32]. Several phase I and II trials have demonstrated
isolated cases of antitumor activity of anti-IGF1R antibodies
in ES [33, 34]. COG has an open phase II study (ADVL0821)
looking at cixutumumab, an anti-IGF1 receptor monoclonal
antibody. Bevacizumab, a monoclonal antibody to VEGF
that is FDA approved in certain cancers, is currently under
investigation and has shown antitumor activity in xenograft
models [20]. Although there is no current known ligand for
CD99,invitrostudiesonEScelllineshavedemonstratedthat
CD99 binding and silencing by speciﬁc antibodies induces
rapid tumor cell death. CD99 is also highly expressed in
humanhematopoieticstemcellsaswellasinseveralcelltypes
in the pancreas and gonads and is likely the reason why clini-
caltrialsusinganti-CD99antibodieshaveyettobeattempted
[35]. Targeted therapy holds promise not only for improving
outcomes for patients with ES but also for reducing exposure
to conventional chemoradiotherapy and its side eﬀects.
The known potential of immune cells to recognize and
kill tumor cells has led to the emergence of vaccine therapy
strategies for refractory solid tumors including ES. Two
cancer/testis (CT) antigens have been identiﬁed as being
highly expressed in ES cells, namely XAGE-1 and LIPI
[36]. These CT antigens are diﬀerentiation antigens whose
expression is restricted to normal gametogenic tissues and
certain tumors. One NIH study looked at vaccination with
dendritic cells (DCs) pulsed with tumor cell lysates in ES
subjects. DCs are the most potent antigen-presenting cells
(APCs) of the immune system and have the ability to activate
T, B, and NK cells alike. Their approach, however, did not
alter disease outcome, although there was one mixed clinical
response in a patient with recurrent ES [37]. Cho et al.
reported a complete remission of residual tumor in one
patient with ES following autologous SCT and pulsed DC
therapy [38]. The use of NK cells is also currently under
investigation and has shown cytotoxicity against ES cells
both in vitro and in vivo [37]. A recent study from the
University of Tennessee demonstrated that ES cells in vitro
were exquisitely sensitive to activated NK cells [39]. Phase I
trials utilizing NK cell therapy are underway.
4. Conclusion
Survival rates with metastatic and recurrent ES continue
to be dismal with current therapeutic approaches. As such,4 Sarcoma
further improvements in treatment strategies for these
patientsareurgentlyneeded.Datatosupporttheuseofhigh-
dosetherapywithstemcelltransplantationiscontroversialat
best due to the lack of prospective, randomized trials. More
novelapproacheswillfocusontheuseoftargetedtherapeutic
agents which oﬀer the advantage of both increasing cure and
limiting toxicity from chemoradiotherapy.
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